Acadia Pharmaceuticals Drug Fails in Late-Stage Schizophrenia Trial

Posted by |2019-07-22T15:20:55-07:00July 22nd, 2019|

Acadia Pharmaceuticals’ treatment for Parkinson’s disease-related psychosis failed a Phase 3 trial that was studying use of the drug for schizophrenia patients who haven’t fully responded to existing therapies. The company announced the trial failure Monday after market close. Acadia (NASDAQ: ACAD) shares dropped about 4 percent on the news in after-hours trading, falling from […]

Spine-Surgery Medtech Startup Carlsmed Merges With Imaging Company

Posted by |2019-07-22T03:30:05-07:00July 19th, 2019|

Carlsmed, a San Diego-based medical technology company that’s developing personalized spinal implants, has merged with Precisive Surgical, a spine imaging system startup in Seattle. The combined company, which will operate in San Diego under the Carlsmed name, aims to create a platform that will use imaging recognition technology, 3D printing, and other tools to allow […]

Kronos Bio Reels In $105M for Drugs That Hit “Undruggable” Targets

Posted by |2019-07-18T08:54:02-07:00July 18th, 2019|

Kronos Bio has raised $105 million in financing to develop therapies intended to target disease-causing proteins that have so far eluded the best efforts of drug hunters. The Series A round of funding announced Thursday was led by Vida Ventures and Omega Funds. Drugs typically work by either binding to a target site on a […]

Pandion Therapeutics Picks Corvidia’s Rahul Kakkar for CEO

Posted by |2019-07-17T14:41:00-07:00July 17th, 2019|

Rahul Kakkar is the new CEO of Pandion Therapeutics. He has also joined the Cambridge, MA, company’s board of directors. Kakkar was most recently chief medical officer and chief strategy officer of Corvidia Therapeutics. He succeeds Pandion founder Anthony Coyle, who is leaving the company. In other moves, Jo Viney, a founder and chief scientific […]

San Antonio to Honor Regenerative Medicine Pioneer Stephen Badylak

Posted by |2019-07-16T21:01:07-07:00July 16th, 2019|

San Antonio — Ah, to be able to regrow a missing limb like a slimy salamander—a trick long dreamed of by youngsters and scientists alike. Research into such regenerative abilities has increasingly excited the scientific community during the past 30 years as it has gained further insight into the potential of the extracellular matrix, a […]

Kymera CEO Laurent Audoly Departs, Nelllo Mainolfi Named President

Posted by |2019-07-15T06:58:26-07:00July 15th, 2019|

Laurent Audoly, president and CEO of Kymera Therapeutics, is leaving “to pursue new entrepreneurial opportunities,” the Cambridge, MA, company announced Monday. Co-founder and chief scientific officer Nello Mainolfi has been appointed president, overseeing all company operations. He will also continue as CSO. Kymera said a search for a new CEO is underway. In other moves, […]

Athira Taps Alder Ex-Alder Bio Exec Litton as Chief Operating Officer

Posted by |2019-07-14T03:30:11-07:00July 12th, 2019|

Mark Litton has been appointed chief operating officer of Seattle-based Athira Pharma. Litton is the co-founder of Alder BioPharmaceuticals (NASDAQ: ALDR), and was chief business officer at that company until last July. Athira, previously known as M3 Biotechnology, is developing treatments for neurodegenerative disorders. The company is currently enrolling patients in a Phase 1b study […]

Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More

Posted by |2019-07-12T02:00:57-07:00July 12th, 2019|

The life science and healthcare worlds are vast. We often talk about impact in terms of millions of patients and billions of dollars. But these worlds can be small, too. It seems at times we’re never far removed from any one person, through their published papers, social media connections, friends, colleagues, or people they’ve mentored. […]

WI Startup Funding Hit Record in 2018 as VCs Cut Bigger Checks

Posted by |2019-07-10T13:30:15-07:00July 10th, 2019|

A record $300 million was invested in Wisconsin ventures last year, as maturing businesses pulled in larger funding rounds. But a continued decrease in the number of firms raising their first outside capital could signal trouble for the state’s pipeline of budding startups. Those are some of the key takeaways from the latest Wisconsin Portfolio, […]

After Amgen’s Spark, Revolution Med Nabs $100M to Push RAS Cancer Drugs

Posted by |2019-07-09T03:25:58-07:00July 9th, 2019|

In May, Amgen (NASDAQ: AMGN) revealed intriguing data from the first-ever human trial of a drug that targets tumors with a specific mutation to the gene KRAS, which occurs in about one-quarter of all cancers. Amgen showed 30 percent of lung cancer patients with the mutation saw their tumors shrink. Even though the data were […]

As Sangamo Touts Data, BioMarin Preps Hemophilia Gene Therapy For FDA

Posted by |2019-07-08T03:49:24-07:00July 8th, 2019|

[Updated 7/8/19, 9:22 am. See below.] Gene therapy for hemophilia is as close as it’s ever been to market. And the race to get there got more heated this past weekend at a medical meeting in Australia. At the International Society on Thrombosis and Haemostasis meeting in Melbourne, Sangamo Therapeutics (NASDAQ: SGMO) and partner Pfizer […]

Bio Roundup: Duchenne Race, Warren v. Gottlieb, A $599 Genome & More

Posted by |2019-07-08T03:30:08-07:00July 5th, 2019|

As we pause to celebrate the 4th of July, another birthday is top of mind: A third baby whose embryonic DNA was edited by Chinese scientist He Jiankui. As Xconomy reported in November, He hinted about a second pregnancy after his infamous revelation of twins altered with CRISPR gene editing tools. That second pregnancy—a third […]

Load More Posts